ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona

Vall d'Hebron University Hospital at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

Vall d'Hebron University Hospital takes part in 38 sessions at ESMO 2026 in Madrid. Its program covers gastrointestinal cancers and precision treatment, alongside breast, lung and other cancers. It examines whether circulating tumour DNA monitoring can help predict treatment response in pancreatic cancer.

OrganizationESMO 2026 Attendance
Cancer centre & hospital
Public university hospital in Barcelona, Spain, whose campus includes a dedicated oncology research institute, the Vall d'Hebron Institute of Oncology.
Satellite
Fri Oct 23
09:45–11:15
Bristol Myers Squibb - Optimizing the NSCLC Treatment Landscape: Impact for Today and Insights for Tomorrow
with Hospital Universitario Puerta de Hierro Majadahonda, European Institute of Oncology (IEO)
Lung & thoracic cancers
Satellite
Fri Oct 23
10:30–10:50
Building on Established IO to Reach New Heights
Bristol Myers Squibb - Optimizing the NSCLC Treatment Landscape: Impact for Today and Insights for Tomorrow
Lung & thoracic cancers
Satellite
Fri Oct 23
10:50–11:10
Keeping the Patient in the Center
Bristol Myers Squibb - Optimizing the NSCLC Treatment Landscape: Impact for Today and Insights for Tomorrow · with International Cancer Advocacy Network (ICAN), Hospital Universitario Puerta de Hierro Majadahonda, European Institute of Oncology (IEO)
Lung & thoracic cancers
Poster
Fri Oct 23
13:00–15:00
Poster
Fri Oct 23
13:00–15:00
Neuro-oncology and molecular tumor boards in Latin America: A public–private comparison from the RIANO survey
ePoster session 4
Sarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology
Poster
Fri Oct 23
13:00–15:00
Poster
Fri Oct 23
13:00–15:00
Sex as a determinant of molecular profile and therapeutic biomarker landscape in early-onset gastric adenocarcinoma
ePoster session 15
Gastrointestinal cancersBiomarkers & precision oncology
Poster
Fri Oct 23
13:00–15:00
The value of liquid biopsy (LB) in pleural mesothelioma (PM) as a biomarker strategy in clinical trials selection
ePoster session 22
Lung & thoracic cancersBiomarkers & precision oncology
Talk
Fri Oct 23
13:30
Clinician scientist
YO Mentorship session · with University Hospital Essen
Abstract
Fri Oct 23
14:07–14:12
Poster
Fri Oct 23
15:15–16:00
Genomic landscape of cancer of unknown primary (CUP): Prognostic stratification through molecular profiling
Friday Poster Display session 2
Sarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology
Poster
Fri Oct 23
15:15–16:00
Poster
Fri Oct 23
15:15–16:00
Talk
Fri Oct 23
16:15–16:35
Diagnostics and risk stratification of newly diagnosed chronic lymphocytic leukemia
The evolving standards in the management of chronic lymphocytic leukemia
Haematological malignancies
Abstract
Fri Oct 23
17:15–17:20
Talk
Sat Oct 24
08:30–08:45
Targeting the RAS/RAF pathway in CRC: Where do we stand and future perspectives
Closing the gap: Promising therapeutic modalities in colorectal cancer
Gastrointestinal cancers
Poster
Sat Oct 24
12:00–12:45
Association between disease control and patient-reported functioning and quality of life in the ASCENT-03 study
Saturday Poster Display session 3
Breast cancerNursing & supportive care
Poster
Sat Oct 24
12:00–12:45
Satellite
Sat Oct 24
13:00–13:05
Welcome & Introductions
AstraZeneca - Advancing 1L Breast Cancer Care Across Subtypes: Recent Developments and Future Directions
Breast cancer
Satellite
Sat Oct 24
13:20–13:40
Anti-EGFR and BRAF inhibitor combinations: The cutting edge of treatment for BRAF mt mCRC
Merck Healthcare KGaA - Striving for more: The cutting edge of therapeutic developments in mCRC
Gastrointestinal cancers
Satellite
Sat Oct 24
13:55–14:25
Exploring the evolving 1L HER2+ BC landscape
AstraZeneca - Advancing 1L Breast Cancer Care Across Subtypes: Recent Developments and Future Directions
Breast cancer
Satellite
Sat Oct 24
14:25–14:30
Close
AstraZeneca - Advancing 1L Breast Cancer Care Across Subtypes: Recent Developments and Future Directions
Breast cancer
Chair
Sat Oct 24
14:45–16:15
Emerging therapies in endocrine and neuroendocrine neoplasms
with Geneva University Hospitals (HUG)
Sarcoma, CNS, head & neck and rare cancers
Chair
Sat Oct 24
14:45–16:15
Rare GU cancers
with University of Cambridge
Genitourinary cancers
Talk
Sat Oct 24
15:30–15:45
Papillary RCC
Rare GU cancers
Genitourinary cancers
Talk
Sun Oct 25
08:30–08:50
Clinical staging and characterization of patients: Upfront surgery vs neoadjuvant therapy
Personalising treatment for patients with early stage HR+ breast cancer
Breast cancer
Talk
Sun Oct 25
09:00
Follow-up for patients with tumour predisposition syndromes
YO Clinical case discussions · with Hacettepe University
Poster
Sun Oct 25
12:00–12:45
Poster
Sun Oct 25
12:00–12:45
Early postoperative recurrence identifies a biologically aggressive KRAS/MAPK-enriched phenotype in cholangiocarcinoma
Sunday Poster Display session 2
Gastrointestinal cancersBiomarkers & precision oncology
Poster
Sun Oct 25
12:00–12:45
Real-world outcomes according to chemotherapy sequencing in advanced pancreatic ductal adenocarcinoma (PDAC)
Sunday Poster Display session 4
Gastrointestinal cancers
Poster
Sun Oct 25
12:00–12:45
Unveiling early-onset pancreatic cancer: Clinical, molecular and therapeutic insights from a real-world cohort
Sunday Poster Display session 4
Gastrointestinal cancers
Satellite
Sun Oct 25
13:00–14:30
Pierre Fabre Laboratories - BRAFV600E-mutant mCRC: Precision medicine in practice
Gastrointestinal cancersBiomarkers & precision oncology
Satellite
Sun Oct 25
13:00–13:03
Welcome and introductions
Pierre Fabre Laboratories - BRAFV600E-mutant mCRC: Precision medicine in practice
Gastrointestinal cancersBiomarkers & precision oncology
Satellite
Sun Oct 25
13:03–13:10
The CRC mutational landscape
Pierre Fabre Laboratories - BRAFV600E-mutant mCRC: Precision medicine in practice
Gastrointestinal cancersBiomarkers & precision oncology
Satellite
Sun Oct 25
13:55–14:25
From the clinic: Applying precision medicine in practice
Pierre Fabre Laboratories - BRAFV600E-mutant mCRC: Precision medicine in practice · with MD Anderson Cancer Center, Charité – Universitätsmedizin Berlin, Peter MacCallum Cancer Centre
Gastrointestinal cancersBiomarkers & precision oncology
Satellite
Sun Oct 25
14:25–14:30
Future directions and close
Pierre Fabre Laboratories - BRAFV600E-mutant mCRC: Precision medicine in practice
Gastrointestinal cancersBiomarkers & precision oncology
Chair
Sun Oct 25
14:45–16:00
LARC: The essential role of multidisciplinary management of locally advanced rectal cancer
with Memorial Sloan Kettering Cancer Center
Gastrointestinal cancers
Talk
Sun Oct 25
14:45–15:05
Presentation by Expert
Is it time to use ctDNA to guide treatment in early stage NSCLC?
Lung & thoracic cancers
Talk
Sun Oct 25
14:45–14:50
Presentation of case/condition
LARC: The essential role of multidisciplinary management of locally advanced rectal cancer
Gastrointestinal cancers
Talk
Sun Oct 25
16:30–16:45
From bench to bedside and beyond
Extending life, realizing potential: Bridging innovation and implementation in cancer care
Chair
Sun Oct 25
16:30–18:00
Pillars of personalised cancer prevention: The breast cancer case
with Netherlands Cancer Institute
Breast cancer
Talk
Sun Oct 25
16:55–17:20
Early detection: Current approaches in genetic or non genetic high-risk individuals
Pillars of personalised cancer prevention: The breast cancer case
Breast cancer
Talk
Sun Oct 25
18:30–18:45
Presentation of a clinical case of a patient with ROS1-rearranged advanced NSCLC
ESMO Colloquium supported by Eisai - ROS1-rearranged non-small cell lung cancer: Insights in biology, testing and patient management
Lung & thoracic cancers
Abstract
Mon Oct 26
11:07–11:17
Abstract
Mon Oct 26
11:17–11:27
Talk
Mon Oct 26
15:45–16:05
EUnetCCC's role in delivering equitable access to state-of-the-art cancer care
How can the use of ESMO's Clinical Practice Guidelines (CPG) help drive standards of care?
Satellite
Mon Oct 26
19:00–19:25
Integrating HER2-Directed Therapies in the Frontline Setting
Physicians' Education Resourse, LLC (PER) - Show Me the Data: HER2- Mutant NSCLC in Transition – Translating Evidence to Practice
Lung & thoracic cancersBiomarkers & precision oncology

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Vall d'Hebron University Hospital

Tell us what you sell and we’ll find the people at Vall d'Hebron University Hospital most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction